Clinical Lymphoma Myeloma and Leukemia 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm associated with the BCR::ABL1 fusion protein resulting in the uncontrolled production of granulocytes.1 In 2022 it was estimated that approximately 8860 people would be diagnosed with CML in the United States.2 Tyrosine kinase inhibitors (TKIs) have dramatically improved the 10-year survival rate of patients with CML from 20% to 80%.3-5 There are four TKIs approved by the US Food and Drug Administration as first-line (1L) therapy for treating patients who have CML: imatinib (2000), dasatinib (2006), nilotinib (2007), and bosutinib (2012). (Source: Clinical Lym...
Source: Clinical Lymphoma, Myeloma and Leukemia - October 19, 2023 Category: Hematology Authors: Andrew J. Klink, Scott J. Keating, John Brokars, Bruce Feinberg, Elias Jabbour Tags: Original Study Source Type: research
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up
We report long-term follow up on a clinical trial of pembrolizumab with R-CHOP in 30 adults with untreated DLBCL. With 5-year follow up, we observed durable responses in most patients, without relapses in patients with PD-L1 tumor expression. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 17, 2023 Category: Hematology Authors: Carrie Ho, Ajay K. Gopal, Brian G. Till, Mazyar Shadman, Ryan C. Lynch, Andrew J. Cowan, Qian V. Wu, Jenna Voutsinas, Heather A. Rasmussen, Katherine Blue, Chaitra S. Ujjani, Ryan D. Cassaday, Jonathan R. Fromm, Min Fang, Stephen D. Smith Tags: Original Study Source Type: research
Pembrolizumab with R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy and Safety with Long-Term Follow-Up
: While generally ineffective in relapsed diffuse large B cell lymphoma (DLBCL), immune checkpoint inhibitors (ICIs) may hold greater promise in untreated, immunocompetent patients. We previously reported safety and early efficacy of pembrolizumab plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (PR-CHOP) in a phase 1 trial of untreated DLBCL, noting responses in 90% of patients (complete response 77%) and a 2-year progression-free survival (PFS) of 83%. We herein report long-term safety and efficacy at 5-year follow up. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 17, 2023 Category: Hematology Authors: Carrie Ho, Ajay K. Gopal, Brian G. Till, Mazyar Shadman, Ryan C. Lynch, Andrew J. Cowan, Qian V. Wu, Jenna Voutsinas, Heather A. Rasmussen, Katherine Blue, Chaitra S. Ujjani, Ryan D. Cassaday, Jonathan R. Fromm, Min Fang, Stephen D. Smith Tags: Original Study Source Type: research
Outcome of Multiple Myeloma Patients With Hepatitis B Surface Antigen: Korean Multiple Myeloma Working Party 2103 Study
In this nationwide, retrospective analysis, the incidence of hepatitis B virus reactivation (HBVr) was significantly decreased by using antiviral prophylaxis. The overall survival was not different between patients with or without HBVr. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 14, 2023 Category: Hematology Authors: Jun Ho Yi, Jung Lim Lee, Yoo Jin Lee, Hye Jin Kang, Young Hoon Park, Young Jin Yuh, Sung-Nam Lim, Hyo Jung Kim, Sung-Hoon Jung, Je-Jung Lee, Hee Jeong Cho, Joon Ho Moon, Ho-Young Yhim, Kihyun Kim Tags: Original Study Source Type: research
Outcome of Multiple Myeloma Patients With Hepatitis Surface Antigen: Korean Multiple Myeloma Working Party 2103 Study
In this nationwide, retrospective analysis, the incidence of hepatitis B virus reactivation (HBVr) was significantly decreased by using antiviral prophylaxis. The overall survival was not different between patients with or without HBVr. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 14, 2023 Category: Hematology Authors: Jun Ho Yi, Jung Lim Lee, Yoo Jin Lee, Hye Jin Kang, Young Hoon Park, Young Jin Yuh, Sung-Nam Lim, Hyo Jung Kim, Sung-Hoon Jung, Je-Jung Lee, Hee Jeong Cho, Joon Ho Moon, Ho-Young Yhim, Kihyun Kim Tags: Original Study Source Type: research
Outcome of multiple myeloma patients with Hepatitis surface antigen:Korean Multiple myeloma working party 2103 study
Hepatitis B virus reactivation (HBVr) is a well-known complication of systemic chemotherapy for particularly hematologic malignancies in HBV carriers. We performed a multicenter retrospective study to investigate the incidence and risk factors of HBVr in patients with hepatitis B surface antigen (HBsAg)-positive multiple myeloma (MM). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 14, 2023 Category: Hematology Authors: Jun Ho Yi, Jung Lim Lee, Yoo Jin Lee, Hye Jin Kang, Young Hoon Park, Young Jin Yuh, Sung-Nam Lim, Hyo Jung Kim, Sung-Hoon Jung, Je-Jung Lee, Hee Jeong Cho, Joon Ho Moon, Ho-Young Yhim, Kihyun Kim Tags: Original Study Source Type: research
Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting
In multiple myeloma (MM), improving our understanding of routine clinical practice and the effectiveness of agents outside of clinical trials is important. TOURMALINE-MM1 data resulted in approval of ixazomib for MM patients who have received ≥1 prior therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 13, 2023 Category: Hematology Authors: Heinz Ludwig, Karthik Ramasamy, Mar ía-Victoria Mateos, Bhuvan Kishore, Varga Gergely, Miriam Ladicka, Alessandra Ori, Lucia Simoni, Nawal Bent-Ennakhil, Dawn Marie Stull, François Gavini, Evangelos Terpos, Roman Hájek Tags: Original Study Source Type: research
Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-cell Lymphoma in the United States
In the United States, the estimated incidence of CTCL is 0.69 cases per 100,000 person-years; it more commonly occurs in men and is typically diagnosed in adults between 50-70 years of age2 Clinical presentation is highly variable, making definitive diagnosis challenging.1 Improvements in awareness and diagnostic accuracy have contributed to the increase in CTCL incidence seen in the United States from 2000 to 2018.3 (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 11, 2023 Category: Hematology Authors: Stefan K. Barta, Nicholas Liu, Maral DerSarkissian, Rose Chang, Mingchen Ye, Mei Sheng Duh, Andy Surinach, Michelle Fanale, Kristina S. Yu Tags: Original Study Source Type: research
Overall Survival in Patients With Multiple Myeloma in the U.S.: A Systematic Literature Review of Racial Disparities
Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of malignant plasma cells in the bone marrow that presents clinically with a range of symptoms, including skeletal lesions, renal insufficiency, anemia, and hypercalcemia.1 MM is considered a rare cancer, accounting for just 10% of hematological malignancies in the United States (U.S.).2,3 It was estimated that 34,470 new MM cases and 12,640 deaths in the U.S. in 2022 would be attributable to MM.4 MM primarily affects older individuals ( ≥70 years) and is more common in men. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 9, 2023 Category: Hematology Authors: Joseph Mikhael, Allie Cichewicz, Elizabeth S. Mearns, Allicia Girvan, Vicki Pierre, Neda Al Rawashdh, Archibong Yellow-Duke, R. Frank Cornell, Michael Nixon Tags: Review Article Source Type: research
Overall Survival in Patients with Multiple Myeloma in the US: A Systematic Literature Review of Racial Disparities
Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of malignant plasma cells in the bone marrow that presents clinically with a range of symptoms, including skeletal lesions, renal insufficiency, anemia, and hypercalcemia. 1 MM is considered a rare cancer, accounting for just 10% of hematological malignancies in the United States (US). 2,3 It was estimated that 34,470 new MM cases and 12,640 deaths in the US in 2022 would be attributable to MM.4 MM primarily affects older individuals ( ≥70 years) and is more common in men. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 9, 2023 Category: Hematology Authors: Joseph Mikhael, Allie Cichewicz, Elizabeth S. Mearns, Allicia Girvan, Vicki Pierre, Neda Al Rawashdh, Archibong Yellow-Duke, R. Frank Cornell, Michael Nixon Tags: Review Article Source Type: research
Survival Outcomes of Limited-Stage Diffuse Large B-cell Lymphoma Treated with Radiation Therapy
Patients with favorable risk limited-stage (LS) diffuse large b-cell lymphoma (DLBCL) have shown excellent outcomes without radiotherapy (RT). However, the role of RT for the remainder of LS-DLBCL patients is less well defined. We aimed to investigate whether the addition of RT provided an overall survival (OS) benefit in a real-world cohort of LS-DLBCL patients based on primary site at presentation. Retrospective data from 39,745 patients with stage I and II DLBCL treated with front-line combination chemotherapy alone or followed by RT were identified using the National Cancer Database from 2004 to 2015. (Source: Clinical...
Source: Clinical Lymphoma, Myeloma and Leukemia - October 9, 2023 Category: Hematology Authors: Daniel A. Ermann, Victoria A. Vardell, Harsh Shah, Lindsey Fitzgerald, Randa Tao, David K. Gaffney, Deborah M. Stephens, Boyu Hu Source Type: research
Full-dose azacitidine in 5 days versus 7 days with a weekend break in myelodysplastic syndromes: a retrospective cohort study
Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders manifesting with morphologic abnormalities and cytopenias, affecting 3 to 4 people in 100,000 per year1 and carrying a sizable risk of progression to acute myeloid leukemia (AML). Standard risk stratification using the Revised International Prognostic Scoring System (IPSS-R) estimates the risk of evolution to AML and the expected survival, with impact in defining treatment goals and selecting therapeutic options. Lower- (IPSS-R ≤ 3.5) and higher-risk MDS (IPSS-R> 3.5) represent two distinct entities, since some patients in the first group may n...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 29, 2023 Category: Hematology Authors: Guilherme Sapinho, L ídia Alves-Ribeiro, Joana Infante, Catarina Jacinto-Correia, Sahir Kalim, João F Lacerda Tags: Original Study Source Type: research
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes
This study examined real-world patient characteristics, treatment patterns, and clinical outcomes of patients with MF treated with fedratinib following ruxolitinib failure in US clinical practice. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 28, 2023 Category: Hematology Authors: John Mascarenhas, Claire Harrison, Tammy A. Schuler, Djibril Liassou, Marn é Garretson, Taavy A. Miller, Sankar Mahadevan, Ali McBride, Derek Tang, Irene S. DeGutis, Pranav Abraham, Jonathan Kish, Bruce A. Feinberg, Aaron T. Gerds Tags: Original Study Source Type: research
Indirect treatment comparisons of mosunetuzumab with third- and later-line treatments for relapsed/refractory follicular lymphoma
No established standard of care exists for relapsed/refractory (RR) follicular lymphoma (FL) after ≥2 prior therapies. We conducted indirect treatment comparisons (ITCs) to compare the efficacy and tolerability of mosunetuzumab with those of available treatments used in this setting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 28, 2023 Category: Hematology Authors: Francesc Bosch, John Kuruvilla, Theodoros P. Vassilakopoulos, Danilo Di Maio, Michael C. Wei, Marie-Helene Blanchet Zumofen, Loretta J. Nastoupil Tags: Original Study Source Type: research
Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 22, 2023 Category: Hematology Source Type: research
